hematopoietic stem cell transplantation Impact of posttransplantation G-CSF on outcomes of allogeneic

[1]  J. Klein,et al.  Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Labopin,et al.  Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Okamura,et al.  The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis , 2003, Bone Marrow Transplantation.

[4]  M. Remberger,et al.  G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IV , 2003, Bone Marrow Transplantation.

[5]  A. Tosti,et al.  Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. , 2001, Blood.

[6]  N. Young,et al.  Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. , 2000, Blood.

[7]  S. Strober,et al.  Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. , 1997, Blood.

[8]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[9]  J. Singer,et al.  Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. , 1995, Bone marrow transplantation.

[10]  W. Fibbe,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. , 1992, Blood.

[11]  C. Tiley,et al.  Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial , 1990, The Lancet.